Better Fit,
Better Medicines

Redefining Drug Discovery and Development in Immuno-Inflammation through Precision Targeting

Experts in the discovery and development of small molecule medicines for immuno-inflammatory diseases

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation.

Our internal portfolio of discovery programmes is advancing towards clinical trials with one programme in the pre-clinical candidate selection stage. We have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

The right drug...

C4XD’s Conformetrix® platform enables rational, accelerated 4D structural drug design with unique measured experimental data

…for the right patient

C4XD’s PatientSeek platform is a groundbreaking precision medicine tool delivering genetics-led patient stratification insights to determine a patient’s likelihood of response to therapy

Our Portfolio

News

View More

Keep up-to-date with C4XD news

Subscribe to the C4XD news stream below